Mohamad Takwa (Epigenica)
Overview
Mohamad Takwa is a prominent figure in the field of biotechnology, known for his contributions to epigenetic research and innovation. He is the co-founder and CEO of Epigenica, a Swedish biotech company that specializes in high-throughput epigenetic screening tools and solutions designed to advance research in fields like oncology, longevity, and drug development. Takwa has a strong academic and entrepreneurial background, holding a PhD in Biotechnology from the Royal Institute of Technology (KTH) in Stockholm. He has co-founded multiple successful biotech and medtech startups, which have resulted in significant exits, including mergers, acquisitions, and public listings on the Swedish exchange market.
Recent Developments
In recent years, Mohamad Takwa and Epigenica have been active in driving the growth of epigenetic research and its applications. Key developments include:
-
June 2025: Epigenica raised $2.2 million to support its commercial expansion and product development, particularly in international markets such as the US. This funding round was led by Voima Ventures with additional backing from Navigare Ventures, Leksell Social Ventures, and Almi Invest. The capital will be used to launch new products and enhance the company's data infrastructure and service capabilities.
-
March 2023: Epigenica closed a €1.8 million funding round to further advance its high-throughput epigenetic solutions. The funds will support the commercialization of their flagship EpiFinder platform, designed for scalable and cost-effective epigenetic biomarker analysis.
-
2024-2025: The company has been preparing to launch additional products under the EpiFinder brand, including EpiFinder Global and EpiFinder cNUC kits. These products are expected to provide significant improvements in the field of epigenetics by offering higher throughput and multiplexing capabilities.
-
Contributions to Multi-Omics: Epigenica's work contributes to the broader field of multi-omics, integrating data from genomics, transcriptomics, proteomics, and metabolomics. This comprehensive approach offers profound insights into biological systems and aids in the development of personalized medicine.
Personal Information
| Attribute | Information |
|---|---|
| Full Name | Mohamad Takwa |
| Born | (Date and Place not publicly available) |
| Nationality | Swedish |
| Occupation | Biotech Entrepreneur, CEO of Epigenica |
| Known For | Co-founding Epigenica, contributions to epigenetics |
| Net Worth | (Not publicly disclosed) |
| Education | PhD in Biotechnology, Royal Institute of Technology (KTH) |
Early Life and Education
Details about Mohamad Takwa's early life and education are somewhat limited in public records. He completed his higher education with a focus on biotechnology, which laid the groundwork for his career in biotech entrepreneurship. Takwa pursued his PhD at the Royal Institute of Technology (KTH) in Stockholm, where he specialized in Biotechnology, a decision that steered his interests towards the burgeoning field of epigenetics. His subsequent academic roles included postdoctoral work at Lund University, which further honed his expertise in the life sciences, specifically in the areas that are at the intersection of technology and biological research.
Career and Notable Achievements
Mohamad Takwa’s professional journey is marked by significant achievements, including:
- Co-Founding Epigenica (2020): Along with Simon Elsässer, Takwa established Epigenica, focusing on developing innovative solutions in epigenetic research.
- Successful Exits: He has a track record of successful exits with other biotech ventures, including mergers and acquisitions, as well as listings on the Swedish stock exchange.
- Product Innovation: Under his leadership, Epigenica developed the proprietary EpiFinder platform, a high-throughput tool for analyzing epigenetic markers at unprecedented scales.
Current Work and Impact
As of 2025, Mohamad Takwa continues to serve as the CEO of Epigenica. His work has had significant impacts in the field of epigenetics, aiding in the development of personalized medicine and advancing the capabilities for drug discovery and diagnostics. Epigenica's technologies are instrumental in providing new insights into the role of epigenetic markers in various diseases, and their applications are expanding the capabilities of researchers globally to better understand and treat conditions affected by genetic regulation.
Conclusion
Mohamad Takwa stands as a significant figure in biotechnology, particularly in the realm of epigenetics. Through his leadership at Epigenica, he continues to drive innovations that not only enhance our understanding of gene expression but also offer practical solutions for personalized medicine and drug development. His work leverages the power of high-throughput screening and multi-omics, placing Epigenica at the forefront of research that could transform how diseases are diagnosed and treated, potentially offering wide-reaching benefits to global healthcare systems.